Mind your act.

ASCO currently recommends MammaPrint genomic risk testing for hormone receptor-positive, HER2-negative, 0-3 nodes positive, high-clinical risk breast cancer patients to help give a thumbs up or thumbs down to chemo.German physicians say hold up: this is not the best interpretation of the MINDACT data. We say do the best with what you have until phase 3 data matures.